Positive updates from the Ampio Pharmaceuticals' (AMPE) pipeline sparked a run to nearly ten dollars last year, before the share price started trickling back down to earth and hit lows of under four bucks in December following a round of negative articles posted on various Internet media outlets that questioned the company's practices, procedures and accuracy of reporting.

Some looked at the late-year slide as a buying opportunity, given the fact that there were still multiple potential catalysts pending on the pipeline front.

This week, that potential still looks to be on track as the company announced on Tuesday favorable results from the "pain score portion of the expansion phase" of the Ampion in Knee (AIK) trial which was recently completed in Australia.

Preliminary analysis of the "pain scores" portion of the trial, according to Tuesday's press release, demonstrated encouraging results and suggested that Ampion might still be a therapeutic alternative to steroids for the treatment of osteoarthritis. The results also confirmed the previously-noted positive safety profile of Ampion, the company's lead product and potential replacement for today's standard-of-care anti-inflammatory treatments.

Given the positive results from this and previous trials, the company and its investors are starting to have eyes for approval. Michael Macaluso, Ampio's Chairman and CEO, stated in Tuesday's release that, "our pre IND meeting request with the FDA was already submitted and given these positive results, we hope to rapidly gain clarity and initiate the definitive trial(s) in the second half of this year."

With those expected trials now slated for the near to mid term agenda, the potential milestone catalysts could continue throughout the new year.

Also on the map is Zertane, a treatment for premature ejaculation for which Ampio has already landed an international partner and is looking to sign more. Results from a Zertane Phase III trial were published in 'European Urology', a publication with a significant global reach in its field, and Ampio attracted its fair share of partnership interest as a result, according to comments made by Ampio's CEO Don Wingerter in an announcement last year.

Another product, Optina, is being developed as an oral treatment for diabetic macular edema (DME) and diabetic retinopathy and provides Ampio with a solid trio of potential large-market product candidates at a time when big pharma is on the prowl to snap up developmental companies with solid pipelines to boast.

Volume, interest and share price have all been slowly rebounding for this company since the December turmoil, so keep an eye on increasing investor interest as the result of another round of solid pipeline news. As is always the case for developmental companies such as this one, the debates about the company's potential will be played out on various media venues, but it's the pipeline that should do the talking.

Tuesday's press release shows that Ampio's pipeline is still doing just that.

Disclosure: Long AMPE.

Add a Comment